img

Global Rheumatoid Arthritis (RA) Medications Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Rheumatoid Arthritis (RA) Medications Market Research Report 2024

Rheumatoid arthritis (RA) is a chronic autoimmune disease of the connective tissue of synovial joints, which is characterized by nonspecific symmetrical inflammation of the surrounding joints, which can lead to progressive destruction of joints and surrounding structures, eventually leading to Sports injuries and disabilities. Rheumatoid arthritis medications are medications developed for different therapeutic targets of this type of disease.
According to Mr Accuracy reports new survey, global Rheumatoid Arthritis (RA) Medications market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rheumatoid Arthritis (RA) Medications market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rheumatoid Arthritis (RA) Medications market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


AbbVie
Pfizer
Boehringer Ingelheim
Bayer
Novartis
Regeneron Pharmaceuticals
Bristol-Myers Squibb
Roche
UCB S.A.
Johnson & Johnson
Amgen
Merck
Mitsubishi Tanabe Pharma
Biogen
Sanofi
Alder
Ablynx
AstraZeneca
Incyte
Galapagos
Hanwha Biologics
Segment by Type
TNFα
CTLA4
CD20
IL-6

Segment by Application


Hospital
Clinic
Others

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Rheumatoid Arthritis (RA) Medications report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Rheumatoid Arthritis (RA) Medications Market Overview
1.1 Product Overview and Scope of Rheumatoid Arthritis (RA) Medications
1.2 Rheumatoid Arthritis (RA) Medications Segment by Type
1.2.1 Global Rheumatoid Arthritis (RA) Medications Market Value Comparison by Type (2024-2034)
1.2.2 TNFα
1.2.3 CTLA4
1.2.4 CD20
1.2.5 IL-6
1.3 Rheumatoid Arthritis (RA) Medications Segment by Application
1.3.1 Global Rheumatoid Arthritis (RA) Medications Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Rheumatoid Arthritis (RA) Medications Market Size Estimates and Forecasts
1.4.1 Global Rheumatoid Arthritis (RA) Medications Revenue 2018-2029
1.4.2 Global Rheumatoid Arthritis (RA) Medications Sales 2018-2029
1.4.3 Global Rheumatoid Arthritis (RA) Medications Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Rheumatoid Arthritis (RA) Medications Market Competition by Manufacturers
2.1 Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Manufacturers (2018-2024)
2.2 Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Rheumatoid Arthritis (RA) Medications Average Price by Manufacturers (2018-2024)
2.4 Global Rheumatoid Arthritis (RA) Medications Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Rheumatoid Arthritis (RA) Medications, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rheumatoid Arthritis (RA) Medications, Product Type & Application
2.7 Rheumatoid Arthritis (RA) Medications Market Competitive Situation and Trends
2.7.1 Rheumatoid Arthritis (RA) Medications Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rheumatoid Arthritis (RA) Medications Players Market Share by Revenue
2.7.3 Global Rheumatoid Arthritis (RA) Medications Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rheumatoid Arthritis (RA) Medications Retrospective Market Scenario by Region
3.1 Global Rheumatoid Arthritis (RA) Medications Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Rheumatoid Arthritis (RA) Medications Global Rheumatoid Arthritis (RA) Medications Sales by Region: 2018-2029
3.2.1 Global Rheumatoid Arthritis (RA) Medications Sales by Region: 2018-2024
3.2.2 Global Rheumatoid Arthritis (RA) Medications Sales by Region: 2024-2029
3.3 Global Rheumatoid Arthritis (RA) Medications Global Rheumatoid Arthritis (RA) Medications Revenue by Region: 2018-2029
3.3.1 Global Rheumatoid Arthritis (RA) Medications Revenue by Region: 2018-2024
3.3.2 Global Rheumatoid Arthritis (RA) Medications Revenue by Region: 2024-2029
3.4 North America Rheumatoid Arthritis (RA) Medications Market Facts & Figures by Country
3.4.1 North America Rheumatoid Arthritis (RA) Medications Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2029)
3.4.3 North America Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Rheumatoid Arthritis (RA) Medications Market Facts & Figures by Country
3.5.1 Europe Rheumatoid Arthritis (RA) Medications Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2029)
3.5.3 Europe Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rheumatoid Arthritis (RA) Medications Market Facts & Figures by Country
3.6.1 Asia Pacific Rheumatoid Arthritis (RA) Medications Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2029)
3.6.3 Asia Pacific Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Rheumatoid Arthritis (RA) Medications Market Facts & Figures by Country
3.7.1 Latin America Rheumatoid Arthritis (RA) Medications Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2029)
3.7.3 Latin America Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rheumatoid Arthritis (RA) Medications Market Facts & Figures by Country
3.8.1 Middle East and Africa Rheumatoid Arthritis (RA) Medications Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2029)
3.8.3 Middle East and Africa Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Rheumatoid Arthritis (RA) Medications Sales by Type (2018-2029)
4.1.1 Global Rheumatoid Arthritis (RA) Medications Sales by Type (2018-2024)
4.1.2 Global Rheumatoid Arthritis (RA) Medications Sales by Type (2024-2029)
4.1.3 Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Type (2018-2029)
4.2 Global Rheumatoid Arthritis (RA) Medications Revenue by Type (2018-2029)
4.2.1 Global Rheumatoid Arthritis (RA) Medications Revenue by Type (2018-2024)
4.2.2 Global Rheumatoid Arthritis (RA) Medications Revenue by Type (2024-2029)
4.2.3 Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Type (2018-2029)
4.3 Global Rheumatoid Arthritis (RA) Medications Price by Type (2018-2029)
5 Segment by Application
5.1 Global Rheumatoid Arthritis (RA) Medications Sales by Application (2018-2029)
5.1.1 Global Rheumatoid Arthritis (RA) Medications Sales by Application (2018-2024)
5.1.2 Global Rheumatoid Arthritis (RA) Medications Sales by Application (2024-2029)
5.1.3 Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Application (2018-2029)
5.2 Global Rheumatoid Arthritis (RA) Medications Revenue by Application (2018-2029)
5.2.1 Global Rheumatoid Arthritis (RA) Medications Revenue by Application (2018-2024)
5.2.2 Global Rheumatoid Arthritis (RA) Medications Revenue by Application (2024-2029)
5.2.3 Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Application (2018-2029)
5.3 Global Rheumatoid Arthritis (RA) Medications Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.1.4 AbbVie Rheumatoid Arthritis (RA) Medications Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Pfizer Rheumatoid Arthritis (RA) Medications Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Boehringer Ingelheim Rheumatoid Arthritis (RA) Medications Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Bayer Rheumatoid Arthritis (RA) Medications Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Novartis Rheumatoid Arthritis (RA) Medications Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Regeneron Pharmaceuticals
6.6.1 Regeneron Pharmaceuticals Corporation Information
6.6.2 Regeneron Pharmaceuticals Description and Business Overview
6.6.3 Regeneron Pharmaceuticals Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Regeneron Pharmaceuticals Rheumatoid Arthritis (RA) Medications Product Portfolio
6.6.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Medications Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Roche
6.8.1 Roche Corporation Information
6.8.2 Roche Description and Business Overview
6.8.3 Roche Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Roche Rheumatoid Arthritis (RA) Medications Product Portfolio
6.8.5 Roche Recent Developments/Updates
6.9 UCB S.A.
6.9.1 UCB S.A. Corporation Information
6.9.2 UCB S.A. Description and Business Overview
6.9.3 UCB S.A. Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.9.4 UCB S.A. Rheumatoid Arthritis (RA) Medications Product Portfolio
6.9.5 UCB S.A. Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Johnson & Johnson Rheumatoid Arthritis (RA) Medications Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 Amgen
6.11.1 Amgen Corporation Information
6.11.2 Amgen Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.11.3 Amgen Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Amgen Rheumatoid Arthritis (RA) Medications Product Portfolio
6.11.5 Amgen Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.12.3 Merck Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Merck Rheumatoid Arthritis (RA) Medications Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Mitsubishi Tanabe Pharma
6.13.1 Mitsubishi Tanabe Pharma Corporation Information
6.13.2 Mitsubishi Tanabe Pharma Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.13.3 Mitsubishi Tanabe Pharma Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Mitsubishi Tanabe Pharma Rheumatoid Arthritis (RA) Medications Product Portfolio
6.13.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.14 Biogen
6.14.1 Biogen Corporation Information
6.14.2 Biogen Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.14.3 Biogen Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Biogen Rheumatoid Arthritis (RA) Medications Product Portfolio
6.14.5 Biogen Recent Developments/Updates
6.15 Sanofi
6.15.1 Sanofi Corporation Information
6.15.2 Sanofi Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.15.3 Sanofi Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Sanofi Rheumatoid Arthritis (RA) Medications Product Portfolio
6.15.5 Sanofi Recent Developments/Updates
6.16 Alder
6.16.1 Alder Corporation Information
6.16.2 Alder Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.16.3 Alder Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.16.4 Alder Rheumatoid Arthritis (RA) Medications Product Portfolio
6.16.5 Alder Recent Developments/Updates
6.17 Ablynx
6.17.1 Ablynx Corporation Information
6.17.2 Ablynx Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.17.3 Ablynx Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Ablynx Rheumatoid Arthritis (RA) Medications Product Portfolio
6.17.5 Ablynx Recent Developments/Updates
6.18 AstraZeneca
6.18.1 AstraZeneca Corporation Information
6.18.2 AstraZeneca Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.18.3 AstraZeneca Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.18.4 AstraZeneca Rheumatoid Arthritis (RA) Medications Product Portfolio
6.18.5 AstraZeneca Recent Developments/Updates
6.19 Incyte
6.19.1 Incyte Corporation Information
6.19.2 Incyte Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.19.3 Incyte Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Incyte Rheumatoid Arthritis (RA) Medications Product Portfolio
6.19.5 Incyte Recent Developments/Updates
6.20 Galapagos
6.20.1 Galapagos Corporation Information
6.20.2 Galapagos Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.20.3 Galapagos Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.20.4 Galapagos Rheumatoid Arthritis (RA) Medications Product Portfolio
6.20.5 Galapagos Recent Developments/Updates
6.21 Hanwha Biologics
6.21.1 Hanwha Biologics Corporation Information
6.21.2 Hanwha Biologics Rheumatoid Arthritis (RA) Medications Description and Business Overview
6.21.3 Hanwha Biologics Rheumatoid Arthritis (RA) Medications Sales, Revenue and Gross Margin (2018-2024)
6.21.4 Hanwha Biologics Rheumatoid Arthritis (RA) Medications Product Portfolio
6.21.5 Hanwha Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rheumatoid Arthritis (RA) Medications Industry Chain Analysis
7.2 Rheumatoid Arthritis (RA) Medications Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rheumatoid Arthritis (RA) Medications Production Mode & Process
7.4 Rheumatoid Arthritis (RA) Medications Sales and Marketing
7.4.1 Rheumatoid Arthritis (RA) Medications Sales Channels
7.4.2 Rheumatoid Arthritis (RA) Medications Distributors
7.5 Rheumatoid Arthritis (RA) Medications Customers
8 Rheumatoid Arthritis (RA) Medications Market Dynamics
8.1 Rheumatoid Arthritis (RA) Medications Industry Trends
8.2 Rheumatoid Arthritis (RA) Medications Market Drivers
8.3 Rheumatoid Arthritis (RA) Medications Market Challenges
8.4 Rheumatoid Arthritis (RA) Medications Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Rheumatoid Arthritis (RA) Medications Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Rheumatoid Arthritis (RA) Medications Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Rheumatoid Arthritis (RA) Medications Market Competitive Situation by Manufacturers in 2022
Table 4. Global Rheumatoid Arthritis (RA) Medications Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Rheumatoid Arthritis (RA) Medications Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Rheumatoid Arthritis (RA) Medications Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Rheumatoid Arthritis (RA) Medications Average Price (USD/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Rheumatoid Arthritis (RA) Medications, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Rheumatoid Arthritis (RA) Medications, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Rheumatoid Arthritis (RA) Medications, Product Type & Application
Table 12. Global Key Manufacturers of Rheumatoid Arthritis (RA) Medications, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Rheumatoid Arthritis (RA) Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rheumatoid Arthritis (RA) Medications as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Rheumatoid Arthritis (RA) Medications Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Rheumatoid Arthritis (RA) Medications Sales by Region (2018-2024) & (K Units)
Table 18. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Region (2018-2024)
Table 19. Global Rheumatoid Arthritis (RA) Medications Sales by Region (2024-2029) & (K Units)
Table 20. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Region (2024-2029)
Table 21. Global Rheumatoid Arthritis (RA) Medications Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Region (2018-2024)
Table 23. Global Rheumatoid Arthritis (RA) Medications Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Region (2024-2029)
Table 25. North America Rheumatoid Arthritis (RA) Medications Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2024) & (K Units)
Table 27. North America Rheumatoid Arthritis (RA) Medications Sales by Country (2024-2029) & (K Units)
Table 28. North America Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Rheumatoid Arthritis (RA) Medications Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Rheumatoid Arthritis (RA) Medications Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2024) & (K Units)
Table 32. Europe Rheumatoid Arthritis (RA) Medications Sales by Country (2024-2029) & (K Units)
Table 33. Europe Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Rheumatoid Arthritis (RA) Medications Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Rheumatoid Arthritis (RA) Medications Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Rheumatoid Arthritis (RA) Medications Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Rheumatoid Arthritis (RA) Medications Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Rheumatoid Arthritis (RA) Medications Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Rheumatoid Arthritis (RA) Medications Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Rheumatoid Arthritis (RA) Medications Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Rheumatoid Arthritis (RA) Medications Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Rheumatoid Arthritis (RA) Medications Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Rheumatoid Arthritis (RA) Medications Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Rheumatoid Arthritis (RA) Medications Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Rheumatoid Arthritis (RA) Medications Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Rheumatoid Arthritis (RA) Medications Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Rheumatoid Arthritis (RA) Medications Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Rheumatoid Arthritis (RA) Medications Sales (K Units) by Type (2018-2024)
Table 51. Global Rheumatoid Arthritis (RA) Medications Sales (K Units) by Type (2024-2029)
Table 52. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Type (2018-2024)
Table 53. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Type (2024-2029)
Table 54. Global Rheumatoid Arthritis (RA) Medications Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Rheumatoid Arthritis (RA) Medications Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Type (2018-2024)
Table 57. Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Type (2024-2029)
Table 58. Global Rheumatoid Arthritis (RA) Medications Price (USD/Unit) by Type (2018-2024)
Table 59. Global Rheumatoid Arthritis (RA) Medications Price (USD/Unit) by Type (2024-2029)
Table 60. Global Rheumatoid Arthritis (RA) Medications Sales (K Units) by Application (2018-2024)
Table 61. Global Rheumatoid Arthritis (RA) Medications Sales (K Units) by Application (2024-2029)
Table 62. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Application (2018-2024)
Table 63. Global Rheumatoid Arthritis (RA) Medications Sales Market Share by Application (2024-2029)
Table 64. Global Rheumatoid Arthritis (RA) Medications Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Rheumatoid Arthritis (RA) Medications Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Application (2018-2024)
Table 67. Global Rheumatoid Arthritis (RA) Medications Revenue Market Share by Application (2024-2029)
Table 68. Global Rheumatoid Arthritis (RA) Medications Price (USD/Unit) by Application (2018-2024)
Table 69. Global Rheumatoid Arthritis (RA) Medications Price (USD/Unit) by Application (2024-2029)
Table 70. AbbVie Corporation Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 73. AbbVie Rheumatoid Arthritis (RA) Medications Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Pfizer Corporation Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 78. Pfizer Rheumatoid Arthritis (RA) Medications Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 83. Boehringer Ingelheim Rheumatoid Arthritis (RA) Medications Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Bayer Corporation Information
Table 86. Bayer Description and Business Overview
Table 87. Bayer Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 88. Bayer Rheumatoid Arthritis (RA) Medications Product
Table 89. Bayer Recent Developments/Updates
Table 90. Novartis Corporation Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 93. Novartis Rheumatoid Arthritis (RA) Medications Product
Table 94. Novartis Recent Developments/Updates
Table 95. Regeneron Pharmaceuticals Corporation Information
Table 96. Regeneron Pharmaceuticals Description and Business Overview
Table 97. Regeneron Pharmaceuticals Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 98. Regeneron Pharmaceuticals Rheumatoid Arthritis (RA) Medications Product
Table 99. Regeneron Pharmaceuticals Recent Developments/Updates
Table 100. Bristol-Myers Squibb Corporation Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 103. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Medications Product
Table 104. Bristol-Myers Squibb Recent Developments/Updates
Table 105. Roche Corporation Information
Table 106. Roche Description and Business Overview
Table 107. Roche Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 108. Roche Rheumatoid Arthritis (RA) Medications Product
Table 109. Roche Recent Developments/Updates
Table 110. UCB S.A. Corporation Information
Table 111. UCB S.A. Description and Business Overview
Table 112. UCB S.A. Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 113. UCB S.A. Rheumatoid Arthritis (RA) Medications Product
Table 114. UCB S.A. Recent Developments/Updates
Table 115. Johnson & Johnson Corporation Information
Table 116. Johnson & Johnson Description and Business Overview
Table 117. Johnson & Johnson Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. Johnson & Johnson Rheumatoid Arthritis (RA) Medications Product
Table 119. Johnson & Johnson Recent Developments/Updates
Table 120. Amgen Corporation Information
Table 121. Amgen Description and Business Overview
Table 122. Amgen Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 123. Amgen Rheumatoid Arthritis (RA) Medications Product
Table 124. Amgen Recent Developments/Updates
Table 125. Merck Corporation Information
Table 126. Merck Description and Business Overview
Table 127. Merck Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 128. Merck Rheumatoid Arthritis (RA) Medications Product
Table 129. Merck Recent Developments/Updates
Table 130. Mitsubishi Tanabe Pharma Corporation Information
Table 131. Mitsubishi Tanabe Pharma Description and Business Overview
Table 132. Mitsubishi Tanabe Pharma Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 133. Mitsubishi Tanabe Pharma Rheumatoid Arthritis (RA) Medications Product
Table 134. Mitsubishi Tanabe Pharma Recent Developments/Updates
Table 135. Biogen Corporation Information
Table 136. Biogen Description and Business Overview
Table 137. Biogen Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 138. Biogen Rheumatoid Arthritis (RA) Medications Product
Table 139. Biogen Recent Developments/Updates
Table 140. Sanofi Corporation Information
Table 141. Sanofi Description and Business Overview
Table 142. Sanofi Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 143. Sanofi Rheumatoid Arthritis (RA) Medications Product
Table 144. Sanofi Recent Developments/Updates
Table 145. Alder Corporation Information
Table 146. Alder Description and Business Overview
Table 147. Alder Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 148. Alder Rheumatoid Arthritis (RA) Medications Product
Table 149. Alder Recent Developments/Updates
Table 150. Ablynx Corporation Information
Table 151. Ablynx Description and Business Overview
Table 152. Ablynx Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 153. Ablynx Rheumatoid Arthritis (RA) Medications Product
Table 154. Ablynx Recent Developments/Updates
Table 155. AstraZeneca Corporation Information
Table 156. AstraZeneca Description and Business Overview
Table 157. AstraZeneca Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 158. AstraZeneca Rheumatoid Arthritis (RA) Medications Product
Table 159. AstraZeneca Recent Developments/Updates
Table 160. Incyte Corporation Information
Table 161. Incyte Description and Business Overview
Table 162. Incyte Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 163. Incyte Rheumatoid Arthritis (RA) Medications Product
Table 164. Incyte Recent Developments/Updates
Table 165. Galapagos Corporation Information
Table 166. Galapagos Description and Business Overview
Table 167. Galapagos Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 168. Galapagos Rheumatoid Arthritis (RA) Medications Product
Table 169. Galapagos Recent Developments/Updates
Table 170. Hanwha Biologics Corporation Information
Table 171. Hanwha Biologics Description and Business Overview
Table 172. Hanwha Biologics Rheumatoid Arthritis (RA) Medications Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 173. Hanwha Biologics Rheumatoid Arthritis (RA) Medications Product
Table 174. Hanwha Biologics Recent Developments/Updates
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Rheumatoid Arthritis (RA) Medications Distributors List
Table 178. Rheumatoid Arthritis (RA) Medications Customers List
Table 179. Rheumatoid Arthritis (RA) Medications Market Trends
Table 180. Rheumatoid Arthritis (RA) Medications Market Drivers
Table 181. Rheumatoid Arthritis (RA) Medications Market Challenges
Table 182. Rheumatoid Arthritis (RA) Medications Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Rheumatoid Arthritis (RA) Medications
Figure 2. Global Rheumatoid Arthritis (RA) Medications Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Rheumatoid Arthritis (RA) Medications Market Share by Type in 2022 & 2029
Figure 4. TNFα Product Picture
Figure 5. CTLA4 Product Picture
Figure 6. CD20 Product Picture
Figure 7. IL-6 Product Picture
Figure 8. Global Rheumatoid Arthritis (RA) Medications Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Rheumatoid Arthritis (RA) Medications Market Share by Application in 2022 & 2029
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Rheumatoid Arthritis (RA) Medications Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Rheumatoid Arthritis (RA) Medications Market Size (2018-2029) & (US$ Million)
Figure 15. Global Rheumatoid Arthritis (RA) Medications Sales (2018-2029) & (K Units)
Figure 16. Global Rheumatoid Arthritis (RA) Medications Average Price (USD/Unit) & (2018-2029)
Figure 17. Rheumatoid Arthritis (RA) Medications Report Years Considered
Figure 18. Rheumatoid Arthritis (RA) Medications Sales Share by Manufacturers in 2022
Figure 19. Global Rheumatoid Arthritis (RA) Medications Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Rheumatoid Arthritis (RA) Medications Players: Market Share by Revenue in 2022
Figure 21. Rheumatoid Arthritis (RA) Medications Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Rheumatoid Arthritis (RA) Medications Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America Rheumatoid Arthritis (RA) Medications Sales Market Share by Country (2018-2029)
Figure 24. North America Rheumatoid Arthritis (RA) Medications Revenue Market Share by Country (2018-2029)
Figure 25. U.S. Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe Rheumatoid Arthritis (RA) Medications Sales Market Share by Country (2018-2029)
Figure 28. Europe Rheumatoid Arthritis (RA) Medications Revenue Market Share by Country (2018-2029)
Figure 29. Germany Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific Rheumatoid Arthritis (RA) Medications Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific Rheumatoid Arthritis (RA) Medications Revenue Market Share by Region (2018-2029)
Figure 36. China Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Taiwan Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Indonesia Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Thailand Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Malaysia Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Philippines Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Latin America Rheumatoid Arthritis (RA) Medications Sales Market Share by Country (2018-2029)
Figure 47. Latin America Rheumatoid Arthritis (RA) Medications Revenue Market Share by Country (2018-2029)
Figure 48. Mexico Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Brazil Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Argentina Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa Rheumatoid Arthritis (RA) Medications Sales Market Share by Country (2018-2029)
Figure 52. Middle East & Africa Rheumatoid Arthritis (RA) Medications Revenue Market Share by Country (2018-2029)
Figure 53. Turkey Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. U.A.E Rheumatoid Arthritis (RA) Medications Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Global Sales Market Share of Rheumatoid Arthritis (RA) Medications by Type (2018-2029)
Figure 57. Global Revenue Market Share of Rheumatoid Arthritis (RA) Medications by Type (2018-2029)
Figure 58. Global Rheumatoid Arthritis (RA) Medications Price (USD/Unit) by Type (2018-2029)
Figure 59. Global Sales Market Share of Rheumatoid Arthritis (RA) Medications by Application (2018-2029)
Figure 60. Global Revenue Market Share of Rheumatoid Arthritis (RA) Medications by Application (2018-2029)
Figure 61. Global Rheumatoid Arthritis (RA) Medications Price (USD/Unit) by Application (2018-2029)
Figure 62. Rheumatoid Arthritis (RA) Medications Value Chain
Figure 63. Rheumatoid Arthritis (RA) Medications Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed